New York State Psychiatric Institute
467
16
22
335
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
15.8%
74 terminated/withdrawn out of 467 trials
81.9%
-4.6% vs industry average
21%
97 trials in Phase 3/4
69%
231 of 335 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (467)
Leveraging Social Networks to Increase COVID-19 Testing Uptake
Role: lead
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
Role: collaborator
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
Role: collaborator
Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia
Role: lead
Personalized and Scalable Cognitive Remediation Approaches
Role: lead
Effects of rTMS on Food Choice in Anorexia Nervosa
Role: lead
A Multimodal Imaging Study of Dopamine in Early Psychosis
Role: lead
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
Role: lead
Exercise and Olanzapine-samidorphan
Role: lead
Glutamatergic Mechanisms: Aim2
Role: lead
Using mHealth to Optimize Pharmacotherapy Regimens
Role: lead
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)
Role: lead
Sleep Interventions and Neurocognitive Outcomes
Role: lead
Scaling up e-Connect in Juvenile Probation Settings
Role: lead
Facilitating Opioid Care Connections
Role: lead
Boricua Youth Study COVID-19 Coping Intervention Study
Role: lead
Brief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems
Role: lead
OnTrackNY's Learning Healthcare System
Role: lead
The Cultural Formulation Interview-Engagement Aid
Role: lead
A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program
Role: collaborator